#biotech — FinScans

News 📈 Stocks

Novartis Pelacarsen Trial Failure Triggers 10% Amgen Sell-Off

September 14, 2026 (57 days ago)

Novartis' failed cardiovascular trial for pelacarsen has roiled the biotech sector, causing a 10% drop in Amgen shares while Eli Lilly maintains…

NVS AMGN IONS +1

🌍 AMERICAS Read More →

News 📈 Stocks

Certara Reports Mixed Q2 2026 Results as Software Growth Battles Services Slump

September 14, 2026 (57 days ago)

Certara's Q2 results highlight a company in transition, balancing strong software momentum against a services slowdown and restructuring costs, while maintaining a…

CERT

🌍 AMERICAS Read More →

News 📈 Stocks

Hair-Loss Drug Stocks Rally 500% as Investors Bet on Next Pharma Goldmine

September 13, 2026 (58 days ago)

Veradermics and Absci lead a surge in hair-loss drug stocks, though clinical risks and the lack of insurance coverage for cosmetic treatments…

MANE ABSI

🌍 AMERICAS Read More →

News 📈 Stocks

Biogen Targets Growth Through Pipeline Diversification and Cost Management

September 12, 2026 (58 days ago)

Biogen pivots toward immunology and nephrology, leveraging 10 Phase III programs and cost-saving initiatives to drive long-term growth and offset legacy portfolio…

BIIB

🌍 AMERICAS Read More →

News 📈 Stocks

BioMarin and Ascendis Resolve Patent Dispute, Shares Rally 5% on Settlement

September 12, 2026 (58 days ago)

BioMarin and Ascendis settle a global patent dispute over the drug Yuviwel, with BioMarin securing a 20% US royalty stream and Ascendis…

BMRN ASND

🌍 GLOBAL Read More →

News 📈 Stocks

Renalytix Shares Rally 7% as UBS Increases Stake and CEO Buys Stock

September 12, 2026 (59 days ago)

Renalytix shares gained 7% after UBS increased its voting stake to 6.62% and CEO James McCullough purchased additional shares, bolstering confidence in…

RNLXY

🌍 AMERICAS Read More →

News 📈 Stocks

CRSP and VKTX: Two Biotech Stocks Poised for Growth in 2027

September 12, 2026 (59 days ago)

CRISPR Therapeutics and Viking Therapeutics offer strong long-term potential as clinical milestones and revenue recognition cycles align for 2027 growth.

CRSP VKTX

🌍 AMERICAS Read More →

News 📈 Stocks

Champions Oncology Revenue Climbs 9% as Q1 EBITDA Hits $671,000

September 12, 2026 (59 days ago)

Champions Oncology posted a 9% revenue increase to $15.2 million in Q1 fiscal 2027, driven by improved service margins and a surge…

CSBR

🌍 AMERICAS Read More →

News 📈 Stocks

Royalty Pharma Limits Losses After Novartis Pelacarsen Phase 3 Trial Failure

September 12, 2026 (59 days ago)

Royalty Pharma pivots to Spinraza royalties to recoup its $500 million investment after the Phase 3 failure of Novartis's cardiovascular drug, pelacarsen.

RPRX IONS NVS

🌍 AMERICAS Read More →

News 📈 Stocks

Teladoc and Recursion Pharmaceuticals Face Dim Outlooks Amid Growth Struggles

September 10, 2026 (61 days ago)

Investors should avoid Teladoc and Recursion Pharmaceuticals as both companies grapple with declining revenue, stiff competition, and unproven business models in a…

LLY NVO BMY

🌍 NORTH AMER Read More →

News 📈 Stocks

Goldman Sachs Identifies Two Biotech IPOs With Over 75% Upside Potential

September 10, 2026 (61 days ago)

Goldman Sachs analyst Salveen Richter initiates coverage on Latigo Biotherapeutics and Braveheart Bio, citing significant clinical potential and large addressable markets for…

LTGO

🌍 NORTH AMER Read More →

News 📈 Stocks

Dow Futures Slip 366 Points as Amgen Slump Weighs on Price-Weighted Index

September 10, 2026 (61 days ago)

Amgen's 6% premarket decline drags the Dow Jones lower, while Novartis trial failures trigger a broader sell-off in related biotech stocks including…

AMGN DJIA

🌍 NORTH AMER Read More →